HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature.
HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature.
复制标题
DOI：
10.7150/jca.4090
复制
发表时间：
2012
影响因子：
3.9
通讯作者：
Hersom M
中科院分区：
文献类型：
--
作者：
Jørgensen JT;Hersom M
通过最近进行的ToGA试验，HER 2已被证明可预测曲妥珠单抗治疗晚期胃癌和胃食管癌。当涉及到预测特性时，情况就不同了。尽管这是20多年前的事实，因为第一个研究表明阳性HER 2状态和预后不良之间的关联发表的问题仍然是有争议的。在本系统综述中，对大量关于HER 2和胃癌的研究进行了综述。纳入本综述的研究应满足以下两个标准。第一个标准：每项研究的患者数量应≥ 100例，并且应通过免疫组织化学（IHC）或原位杂交（ISH）确定HER 2状态。第二个标准：所选文章应包括HER 2状态与生存或相关临床病理学特征之间的相关性分析。共有42篇出版物（共12，749例患者）符合这两项标准，并进行了详细审查。大多数出版物（71%）显示，通过IHC或ISH测量的HER 2阳性状态与生存率差和/或临床病理学特征相关，如浆膜浸润、淋巴结转移、疾病分期或远处转移。基于当前的分析，显示了HER 2作为胃癌中的负性促癌因子的潜在作用的明确趋势，表明HER 2过表达和/或扩增是可能与胃癌发展相关的分子异常。
Through the recent conduct of the ToGA trial, HER2 has shown to be predictive for the treatment with trastuzumab in advanced gastric and gastro-oesophageal cancer. When it comes to the prognostic properties the situation is different. Despite the fact that it is more than 20 years ago since the first studies demonstrating an association between a positive HER2 status and poor prognosis were published the issue is still controversial. In this current systematic review a large number of studies on HER2 and gastric cancer have been reviewed. The studies included in this review should fulfill the following two criteria. First criterion: The number of patients in each study should be ≥ 100, and the HER2 status should have been determined either by immunohistochemistry (IHC) or in situ hybridization (ISH). Second criterion: The selected articles should include an analysis of the association between the HER2 status and survival or relevant clinicopathological characteristics. Forty-two publications with a total of 12,749 patients fulfilled the two criteria and were reviewed in detail. The majority of the publications (71%) showed that a HER2-postive status measured either by IHC or ISH was associated with poor survival and/or clinicopathological characteristics, such as serosal invasion, lymph node metastases, disease stage, or distant metastases. Based on the current analysis a clear trend towards a potential role for HER2 as a negative prognostics factor in gastric cancer was shown, suggesting that HER2 overexpression and/or amplification is a molecular abnormality that might be linked to the development of gastric cancer.
登录
查看更多内容
影响因子：
8.8
作者：
Barros-Silva, J. D.;Leitao, D.;Afonso, L.;Vieira, J.;Dinis-Ribeiro, M.;Fragoso, M.;Bento, M. J.;Santos, L.;Ferreira, P.;Rego, S.;Brandao, C.;Carneiro, F.;Lopes, C.;Schmitt, F.;Teixeira, M. R.
通讯作者：
Teixeira, M. R.
影响因子：
56.9
作者：
COUSSENS, L;YANGFENG, TL;ULLRICH, A
通讯作者：
ULLRICH, A
影响因子：
2.4
作者：
Lee, KE;Lee, HJ;Kim, JP
通讯作者：
Kim, JP
DOI：
10.3233/clo-2009-0497
发表时间：
2010
期刊：
Cellular oncology : the official journal of the International Society for Cellular Oncology
影响因子：
--
作者：
Grabsch H;Sivakumar S;Gray S;Gabbert HE;Müller W
通讯作者：
Müller W
影响因子：
3.7
作者：
Kim, Kab Choong;Koh, Young Wha;Park, Young Soo
通讯作者：
Park, Young Soo